BofA Raises UCB Price Target and EPS Forecasts After FY26 Guidance Increase
Bank of America raised its price target and EPS forecasts for UCB after the company increased its fiscal 2026 guidance. The report attributes the updated outlook to strong performance by two primary pharmaceutical products.